N
Google TrendMONTEZ SWEAT (1000+) — Bears DE Montez Sweat suspended 2 days for drug violation
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:montez sweat1000+rob lowe1000+tanner hudson500+frozen frenzy200+payton pritchard1000+huevo500+winter weather advisory2000+joão cancelo1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Semaglutide versus placeb" (30 stories)

Top Headline Story

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
Lead StoryNaturegeneral
May 22

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5DMTkwV1RIdGsweG9KZEJ4NHV3R0NfX0ZSZ3ZjTzZWN0xxSl9kaFJnOGhZdmgwNEdZRUFjMmJPc2JvRnFybFZoLVE3eHZsYXBaUFhyV0ZEYUpTZ0RiRjlj?oc=5" target="_blank">Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
1000+16m ago

montez sweat

Bears DE Montez Sweat suspended 2 days for drug violation

Filter stories
1000+26m ago

rob lowe

Daily Wire's 'Confession': Details Revealed For James Franco, Rob Lowe Film

Filter stories
500+26m ago

tanner hudson

Bengals tight end Tanner Hudson out for season with torn pec

Filter stories
200+26m ago

frozen frenzy

The top reason to watch every NHL team in the Frozen Frenzy

Filter stories

Search Results for "Semaglutide versus placeb"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial
The Lancetgeneral

Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOSDg4OFVhcTR0OFd4Mnkxa3Mya1g1MkNldHRURXpiblBtUklsOFQ5Mzd1MFpCLTB1Uk1QSm5pMzh2cVRvLTNHUGh5UXZyazVleVhiTWNjNFlKSGtDMzFKZjNLcXhrRHZ5WGNEYVEwZXJlOGVIR3N6TXhSRFNiN3JYRG9ucWtHMHhfeU9J?oc=5" target="_blank">Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Semaglutide as a promising new treatment for alcohol use disorder
News-Medicalgeneral

Semaglutide as a promising new treatment for alcohol use disorder

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxOUm9sakJBOVBpeUx5ME9uTnI3MnBoUWJtUWdJTm1XRjBGY1c3dS1yYU1pWkJLY2Fqc2ZiY1BUdWJ3ek5Na3QtRlk2Q0dYNmVDNGE0SG1Nb2lVSDBzLUZpanpmcUpjREIxRlRuNUpERHd3SDhCTmVqQWNFQVhaSWhUUlBpbkdjbWtWTVBCQWNlN1Q1cXRxU1o4WkJWVE5hQ3o3emFqc1pZU19YUTV4VkY2VURrMA?oc=5" target="_blank">Semaglutide as a promising new treatment for alcohol use disorder</a>  <font color="#6f6f6f">News-Medical</font>

Read Full StoryMore like this
Study: Popular GLP-1 Drug May Slow Down Biological Aging
UC San Diego Todaygeneral

Study: Popular GLP-1 Drug May Slow Down Biological Aging

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxNXzM5UWNIcTVNOGlyT0Q2NjI5TzFEYUZmQU1yLUIxNjNSVHdMNEd6Mm5UMV9QMHJFc0t6dUp5a0hxNGFxOXVnS0E3cnAyX2djdmJUdHJPeWN3aHRWRXJISzRZSDBIQU50djR6WTAyamxPTUJIY0tTVHMyNEh1RlJNWVFMdVNsc09MSm5hcw?oc=5" target="_blank">Study: Popular GLP-1 Drug May Slow Down Biological Aging</a>  <font color="#6f6f6f">UC San Diego Today</font>

Read Full StoryMore like this
GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity, finds small trial
Medical Xpressgeneral

GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity, finds small trial

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxOMjZoZDdneUhuR1I2dVRsRkZwejU2Z3pxSTdhZnVWcXQwLVdFZWpiWnZSVlZxZlBYNXRwQm1sQ19ycFNrYWxob3dnMGxFNzQtTGZXeFBJeGNMbHU2WkJWRi1Mc1B1bF95b1BoZ0czNWM0Nm03ZnQzU0o3d3RCVUw1OA?oc=5" target="_blank">GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity, finds small trial</a>  <font color="#6f6f6f">Medical Xpress</font>

Read Full StoryMore like this
Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide
British Journal of Ophthalmologygeneral

Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide

<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTFAwOGJVSVdsY0RKRV96a3p2V0hEWUNWXzVGYldoSlY2SHVxWVdxeHNLM3REbEdsR09JVTJ1Uy1HbVBsSUtwLWlkR2tmeXBEeFg5Q0dsMkRyVWE4b2NkdmMxYmVxRXZZYVpFdWlzcw?oc=5" target="_blank">Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide</a>  <font color="#6f6f6f">British Journal of Ophthalmology</font>

Read Full StoryMore like this
GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review and meta-analysis
medRxivgeneral

GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review and meta-analysis

<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE5Ya3NwY2I0QlNhWmpQenNUUzUxOE5sUXk1SGw1dEdvcG85dWxrTG5hT25IdGxyUGpOMm91YkZwSVl4cHRlVUFmWkYza1hCYlZmWVRaX29lVVVRMHBSZU01UVZVU3RBV1l5b1Byd3V6Ylp4OENqMEE?oc=5" target="_blank">GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review and meta-analysis</a>  <font color="#6f6f6f">medRxiv</font>

Read Full StoryMore like this
Semaglutide Cuts Heavy Drinking in Alcohol Use Disorder Trial
European Medical Journalgeneral

Semaglutide Cuts Heavy Drinking in Alcohol Use Disorder Trial

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxORjJuUnlqUF9sNHhMRTdRTXpWSUtFWGJEZTd1dF9WaTN6VVlvSGtSam5fVDR1NEdDei14XzBXclY3SDdzV1VnMHVMemFZbWZCblN6bU5aR2V3SkR4TDJoRXRwV2lRZU5jTUt4SV9rbUZvdzhudGtNa19OVE9Cdmhabk5HN3A1NjJLTnJoaEVUWXVsVlZ0WXljZExNcDljX2JzM1hQZ0pR?oc=5" target="_blank">Semaglutide Cuts Heavy Drinking in Alcohol Use Disorder Trial</a>  <font color="#6f6f6f">European Medical Journal</font>

Read Full StoryMore like this
FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results
Applied Clinical Trials Onlinegeneral

FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxONnp3SnR1VmJWdUpzNGJfQ2ZMUmQ0TllxYmVMN3BqcEcyXzJoSWI3T3JfM3FhM25BSmU5VVl3T3dNdW9zSVc1VzBPS1BMQjU1T2NyQko3bUxLcTBFdFJIVHVvQkVfVmtyek04M21aSE5QeWlTVHBPY0JLMjVJRlc1ZXRuT3AzTFBQRWpLMTBpN1h0R2JSZzZKdEQ2ck5taUtFbUVrbA?oc=5" target="_blank">FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results</a>  <font color="#6f6f6f">Applied Clinical Trials Online</font>

Read Full StoryMore like this
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials
The Lancetgeneral

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNbjBaZk1OSS1ZbzBLbjlyMGRMS2daVmViQ0VqUkZQUUdvQ19GSjNJNGJEeXVKU2hWbTloZWFlRkMySUItaGxmOUMtWXJLeXAyZVQxcEZ3S1ViNUFCQkY2Zm5IY1pPS2dGS0ZjcEs4dXJ3dEFSRUZ3NmRtQ1NOZEZWTk9MR3RiTnZEVmYw?oc=5" target="_blank">Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease
NeurologyLivetech

GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQNnVFN1pTUE9SQk8tVHBuZTdMeFlES1lsQWtJbkdVRnpJdFJ5dXh3b3FNM2RKcGhUMEhQNmd4VjNnMDNkYzhDWFZ1US1iTnc0ZWlZNWpNLWRsQjRzZkNENW84U3FkTWQ5X2JEMlBYeTYzbE90S2Z1VXVPVklQazN2dHNwcWdRWlZpZjlxOWlnRzFnR2Qta0kzOXd1a1pwQzVtU2c?oc=5" target="_blank">GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
Semaglutide Fails to Slow Progression of Alzheimer Disease Compared to Placebo: Novo Nordisk Phase 3 Trial Update
Patient Care Onlinetech

Semaglutide Fails to Slow Progression of Alzheimer Disease Compared to Placebo: Novo Nordisk Phase 3 Trial Update

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxNSXVVOHVCTTNVRktaWEZ0bWVSMHhLbndmcnpIaXIwaGF2aWRjcEhkenFsZDY1dnJNbTV1QWZ0MUxBYzF5VWRRcVpiRFpneGNiNDdKTUs5LXdCVUZZbEdzWkZ6TTVKUm5GUFZyRmZSZjNSbnhjRU1ROW41RkdsX0EzQTktM3VyVFFWQV84VTZ0c1c5S0RvYmNwdWFZeTNqMkQ1TkdBU3l0YTFGN3JVTkYxNXRqQk0yNkgzRUh0WG5Mc25VaFp5eVJra0VCczh0bXlKY3VOSW9RNHZHeWlNOVNHUUtRRDJLZw?oc=5" target="_blank">Semaglutide Fails to Slow Progression of Alzheimer Disease Compared to Placebo: Novo Nordisk Phase 3 Trial Update</a>  <font color="#6f6f6f">Patient Care Online</font>

Read Full StoryMore like this
Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial | Signal Transduction and Targeted Therapy
Naturegeneral

Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial | Signal Transduction and Targeted Therapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9hbUNBbHZ0ZVFieDJoZVBkclZ3WXRJN21aT1hvN2ZGRTNXMXlGY2kzRkRQYjRhVFhGanJPejZtS3RURkNWdHl0ZXFxc2hoT25BTXJCcUN6OEpjelZEWFBN?oc=5" target="_blank">Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial | Signal Transduction and Targeted Therapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Semaglutide Fails to Demonstrate Reduction in Alzheimer’s Progression Versus Placebo
HCPLivetech

Semaglutide Fails to Demonstrate Reduction in Alzheimer’s Progression Versus Placebo

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxONE52Z1pRNHkwSFpEMjZjWGVuNmZDM2U5VUhiUVNtV0FhemxWU3BGTlBYLUVBN3Nib3hYaTV2eXBjVTVhbmE0YWJrVW9rcU90VkFOMHNWNC1fYWpTUVNvQngyQnFFZlctcFRkWXN1MFg4Um0tZHlvcGVwZ3VXSjBZc1JIc1M2SExVYUc2VXRTaFRQUXZUcTRoVnJWQlJXZHFIclRxT2ZXU19WWlBTTDJsV2lqZw?oc=5" target="_blank">Semaglutide Fails to Demonstrate Reduction in Alzheimer’s Progression Versus Placebo</a>  <font color="#6f6f6f">HCPLive</font>

Read Full StoryMore like this
Weight loss drug semaglutide helps patients who do not respond to bariatric surgery, research finds
Medical Xpressgeneral

Weight loss drug semaglutide helps patients who do not respond to bariatric surgery, research finds

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQVW9wUllITUNFaHRSTE1HbVR6dGMxYmhoTkNWa292NUVFSTRGbUJ2UmZYUEhNaGU4bkoxQUhhajNMb3lJT09zQnY0SEM1U2JvV283YkJVY3lHSDZULVpTREdSRl9GbXRmR3lSWnY1N2d0YW5fcE5STzM5Tkc5dkZoNTdfTUhYT0tk?oc=5" target="_blank">Weight loss drug semaglutide helps patients who do not respond to bariatric surgery, research finds</a>  <font color="#6f6f6f">Medical Xpress</font>

Read Full StoryMore like this
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
NEJMgeneral

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9JWmZtWlFveDByWjVjbHZkeXVLMzE3VlR3ek9xT2s4ZE4yOXd2ZDZXV3JvVk5GOWJCR1pYTDlrZ0NhZ0RQVnRyNndYa21ZVVNodG1FS3lXdl9rbFdiUlVxNQ?oc=5" target="_blank">A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial
Naturegeneral

Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5vNlY3R0Z0emFLS3ZxUExGOThaVXBKbjdfT3d2U29WSVdVZjUtUUd3dTloend6cl83MnhtcENQR1FXbGN4MTdhVHAxNjZLYW84aTBKUDFfVmNMNjhpNEdv?oc=5" target="_blank">Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
The Lancetworld

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPRUp1dEdHRTBOUHUxNUxSQVM2anRTY1o2VU56Um9XcFBSeDFjUUFsMDFZUjVkdTBNbGs2MTRZeVlmc2VsWUxsSjRtOGQ0MWFFbDJsbTdoMXN5XzN0ZXh1RnQ5X25VT3pORHctZlprVllPMVJibFFNTDJfY1ZhUU5IQU5MVmpCbFBhY1F0QU9XREk4YlNERGc?oc=5" target="_blank">Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
The Lancettech

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOdTU4elpjY1hoTzVzbkhwOWJhLUVjZWlfbWhndUJycFNHS2F5TXFGS1llVzBMOUJmNHJvT09lQUJKNXJCMjlSdjFwelB0eEt1XzhZR0RRcXZ0bldXaUNiUGt0REpoczNsMVJNUWJKUE9iRjB0eURSMl9ndkd0RTEzNnhfbmVCSlVtYzVV?oc=5" target="_blank">Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Naturegeneral

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE96ZGhVSWxDS3Y3UFd1ZDB1UHlHR1drRlV6OUYtWkdoWnNPaTN3X19EV1ZFZDEyMl9DUUZMekFqakNoWGR5enN0Z0NORFdWMHJ3S2E1UDlMNFk5T2pFU2Q0?oc=5" target="_blank">Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Wegovy in a pill? Massive weight loss results revealed
Science Dailygeneral

Wegovy in a pill? Massive weight loss results revealed

<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE1jVmdPU0RnS2FyVFZYYU1uWjRBYVNKemxZNUltRk92MTJHNjNlQU5lVWRJUnRyT2FEVWtoOUFfU1NNZVJ6bVNFSF9SbUQzSlEyaUNvQTlHOEthU2NYSGtnWW5JZmNIZU5uZzZxZ2hjRQ?oc=5" target="_blank">Wegovy in a pill? Massive weight loss results revealed</a>  <font color="#6f6f6f">Science Daily</font>

Read Full StoryMore like this
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
Naturegeneral

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9PQk1lTkxJLXNDMGlzd0lZc3JYOGVzeUxzTjdSRkRrUXp5ZnRwWWZTdS1aZDYxLXRsNnVWRnJlRmlFU2JZVUp3SFM0X2k1TnVESkhKRGdHdnhPTlFfR1dr?oc=5" target="_blank">Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
NEJMworld

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE4xNHBhME0tYUVVTm91Z2Zwb1BPSDlkU2gzMFVKa2NuOWdmVHZ4ZGVHUF8xNF83YzYyZk1iRlFkaUluRmVmNWhOaS1HeURGVHFCcTVuaVFUWTBJWVFjczd3?oc=5" target="_blank">Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial | American Journal of Psychiatry
Psychiatry Onlinegeneral

Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial | American Journal of Psychiatry

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE5fdHBNZ1BJNS1VUW1LTWNVeVBJdUJpZmtFRE5lNGZBT3hRMXVhaWxraXJseDlWTnZLN1cyd095ZU1RSnIzTHdVWG1jUWxHdWlPWkJYV1ZqaG5NMHc0R0hLQzBSNEI2NldFUFE?oc=5" target="_blank">Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial | American Journal of Psychiatry</a>  <font color="#6f6f6f">Psychiatry Online</font>

Read Full StoryMore like this
Is Placebo Still Ethical in Trials of Incretin Therapies?
American Heart Association Journalsgeneral

Is Placebo Still Ethical in Trials of Incretin Therapies?

<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTFAwNl9MYmREejBCSE1SY1p1dUxCMGs0dktxSjFqTEtPcFJ2WVV0aWt0VFZyR0Y5NkFWbGxpSjRzVkFJRVBENklDUUNTdnIybkZVSmlhUnBRWkdLOEtCSU1vNVFqRzl3LWxHSDVLdFBxcHg5bEk?oc=5" target="_blank">Is Placebo Still Ethical in Trials of Incretin Therapies?</a>  <font color="#6f6f6f">American Heart Association Journals</font>

Read Full StoryMore like this
Semaglutide’s Alcohol Data Is Stronger Than Anyone Expected — and the FDA Has No Playbook for It
The Clinical Trial Vanguardgeneral

Semaglutide’s Alcohol Data Is Stronger Than Anyone Expected — and the FDA Has No Playbook for It

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQRDduMTdBRUpaTTBFNzhOVGNuMWRPbTdxbHBsMmdYWnRWd3lLUThYYXNNN3ROR0FtRVgwS1ZNWmF1bFNmbDM1a0VSenVpWXdkV3BHNmh4WU9CSFMydUVaRi1SamNQZUxXdHhKOW9QWmNmQnA0ek9KWlg1ZXBiZXZ4bmFmcmdYcEh4UG9IMFpXcUo2WE1iYW01Rjl5TlJ5bXo1UWdSZFp2eTloY2tXdjU0M0hReFlXNUQ5MTR4NDd5bkhlajlEZkhnYmpXLV9sQ3NPV1ZqTzBFYw?oc=5" target="_blank">Semaglutide’s Alcohol Data Is Stronger Than Anyone Expected — and the FDA Has No Playbook for It</a>  <font color="#6f6f6f">The Clinical Trial Vanguard</font>

Read Full StoryMore like this
Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial
The Lancetgeneral

Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPUklPaTZrUzhTWjd0YTdPaGRQVjdCRG1HeUpfcEFTbncydzdvMmx0NDFfOGhjR1ZwSXhPTXJDWUtrUk13MzF3WktWX2JWU1dEODBla3lxbG5nMXctc2JuN185Y2d5VjBCM04yVlRQR19PSE9zdzlIemtHSTJyVXFNa3J5ZGtOU3FLejA0?oc=5" target="_blank">Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy
Naturegeneral

Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9CelJKNzhrVnFtVDVSNGQ5bnNxOTEtNk5NZWlXUkhFNmNxclRUYkpKNGtXSmZQVmRtV25DYTN3UEZmNWk1V1ZxZWxzeXNMTEY3bEtuWlp1V255cnA0UnNj?oc=5" target="_blank">Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
The Lancetgeneral

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPN2hndkpGUEhVdU5ldjFZTldONjRQeHJWWDB6dzNYaWhDaF8tU3hrUEJTdFkxZ0JTQ3ljZ0FPN243RFZPNFluX0FVR3RySTFicVVnUWF5dGlGNzlZNHVwT0M1V0tKZ3NtNjJfcS1wX05teDIyM3NOZkkxNE5yMldZdjBERVl2OGFuTl9F?oc=5" target="_blank">Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
NEJMtech

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFA3YUt2YmFMdUFrUThlNlJYcVdBT0U0SmhnZ1FHVWluaW1FeVNQV0ZVd01FS2ZDdnRWTTZMeWhTUXE2NFhpOUtHaFdTTVFiU0JvUUJwb2VzZl9RR1dzMGpBMA?oc=5" target="_blank">Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
"Semaglutide versus placeb" — Live Google News Trends & Headlines